Akebia Therapeutics (AKBA) Competitors

$1.02 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.01 -0.01 (-0.49%)

As of 05/22/2026 06:28 PM Eastern

AKBA vs. AVLN, COLL, XERS, MRVI, and CVAC

Should you buy Akebia Therapeutics stock or one of its competitors? MarketBeat compares Akebia Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Akebia Therapeutics include Avalyn Pharma (AVLN), Collegium Pharmaceutical (COLL), Xeris Biopharma (XERS), Maravai LifeSciences (MRVI), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.

How does Akebia Therapeutics compare to Avalyn Pharma?

Akebia Therapeutics (NASDAQ:AKBA) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Avalyn Pharma has lower revenue, but higher earnings than Akebia Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.16	-$5.34M	-$0.08	N/A
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A

Avalyn Pharma has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Avalyn Pharma's return on equity of 0.00% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-8.83%	-62.72%	-5.66%
Avalyn Pharma	N/A	N/A	N/A

33.9% of Akebia Therapeutics shares are held by institutional investors. 4.3% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Avalyn Pharma had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 4 mentions for Avalyn Pharma and 1 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.37 beat Avalyn Pharma's score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Akebia Therapeutics presently has a consensus target price of $4.67, suggesting a potential upside of 357.52%. Avalyn Pharma has a consensus target price of $66.00, suggesting a potential upside of 128.85%. Given Akebia Therapeutics' higher possible upside, equities analysts clearly believe Akebia Therapeutics is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Avalyn Pharma	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Akebia Therapeutics beats Avalyn Pharma on 6 of the 11 factors compared between the two stocks.

How does Akebia Therapeutics compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 2 mentions for Collegium Pharmaceutical and 1 mentions for Akebia Therapeutics. Collegium Pharmaceutical's average media sentiment score of 0.65 beat Akebia Therapeutics' score of 0.37 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

33.9% of Akebia Therapeutics shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Collegium Pharmaceutical has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.42	$62.87M	$2.04	16.70
Akebia Therapeutics	$236.20M	1.16	-$5.34M	-$0.08	N/A

Collegium Pharmaceutical presently has a consensus price target of $57.50, suggesting a potential upside of 68.77%. Akebia Therapeutics has a consensus price target of $4.67, suggesting a potential upside of 357.52%. Given Akebia Therapeutics' higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Collegium Pharmaceutical has a net margin of 9.41% compared to Akebia Therapeutics' net margin of -8.83%. Collegium Pharmaceutical's return on equity of 95.18% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Summary

Collegium Pharmaceutical beats Akebia Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Xeris Biopharma currently has a consensus target price of $10.80, suggesting a potential upside of 74.47%. Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 357.52%. Given Akebia Therapeutics' higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Xeris Biopharma has higher revenue and earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	3.66	$550K	$0.06	103.17
Akebia Therapeutics	$236.20M	1.16	-$5.34M	-$0.08	N/A

Xeris Biopharma has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Xeris Biopharma has a net margin of 3.81% compared to Akebia Therapeutics' net margin of -8.83%. Xeris Biopharma's return on equity of 735.00% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

In the previous week, Xeris Biopharma and Xeris Biopharma both had 1 articles in the media. Xeris Biopharma's average media sentiment score of 0.84 beat Akebia Therapeutics' score of 0.37 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 6.5% of Xeris Biopharma shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Xeris Biopharma beats Akebia Therapeutics on 14 of the 15 factors compared between the two stocks.

How does Akebia Therapeutics compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Maravai LifeSciences has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Maravai LifeSciences currently has a consensus target price of $5.50, suggesting a potential upside of 25.00%. Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 357.52%. Given Akebia Therapeutics' higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Akebia Therapeutics has a net margin of -8.83% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Maravai LifeSciences and Maravai LifeSciences both had 1 articles in the media. Maravai LifeSciences' average media sentiment score of 0.64 beat Akebia Therapeutics' score of 0.37 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Akebia Therapeutics has higher revenue and earnings than Maravai LifeSciences. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	6.12	-$130.77M	-$0.71	N/A
Akebia Therapeutics	$236.20M	1.16	-$5.34M	-$0.08	N/A

Summary

Maravai LifeSciences and Akebia Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Akebia Therapeutics compare to CureVac?

CureVac (NASDAQ:CVAC) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

CureVac presently has a consensus target price of $6.83, suggesting a potential upside of 46.64%. Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 357.52%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

CureVac has higher earnings, but lower revenue than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Akebia Therapeutics	$236.20M	1.16	-$5.34M	-$0.08	N/A

CureVac has a net margin of 199.92% compared to Akebia Therapeutics' net margin of -8.83%. CureVac's return on equity of -23.03% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

In the previous week, Akebia Therapeutics had 1 more articles in the media than CureVac. MarketBeat recorded 1 mentions for Akebia Therapeutics and 0 mentions for CureVac. Akebia Therapeutics' average media sentiment score of 0.37 beat CureVac's score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Akebia Therapeutics	Neutral

17.3% of CureVac shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Akebia Therapeutics beats CureVac on 9 of the 16 factors compared between the two stocks.

Get Akebia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKBA vs. The Competition

Export

Metric	Akebia Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$273.62M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-12.75	17.79	21.21	25.65
Price / Sales	1.16	336.21	554.38	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	10.20	5.86	10.37	7.14
Net Income	-$5.34M	$74.99M	$3.57B	$335.98M
7 Day Performance	13.95%	3.11%	6.40%	4.15%
1 Month Performance	-28.67%	-3.05%	3.53%	2.54%
1 Year Performance	-64.34%	34.38%	34.04%	35.06%

Akebia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKBA Akebia Therapeutics	2.4333 of 5 stars	$1.02 flat	$4.67 +357.5%	-64.3%	$273.62M	$236.20M	N/A	430
AVLN Avalyn Pharma	N/A	$26.63 -10.8%	N/A	N/A	$1.11B	N/A	N/A	51	Analyst Forecast
COLL Collegium Pharmaceutical	2.9549 of 5 stars	$33.65 -0.4%	$57.50 +70.9%	+18.1%	$1.10B	$780.57M	16.50	210
XERS Xeris Biopharma	2.9835 of 5 stars	$6.01 -3.7%	$10.80 +79.7%	+28.2%	$1.08B	$291.85M	100.17	290
MRVI Maravai LifeSciences	3.0769 of 5 stars	$4.08 -1.7%	$5.50 +34.8%	+98.2%	$1.07B	$185.74M	N/A	610	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKBA) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akebia Therapeutics (AKBA) Competitors

AKBA vs. AVLN, COLL, XERS, MRVI, and CVAC

How does Akebia Therapeutics compare to Avalyn Pharma?

Summary

How does Akebia Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Akebia Therapeutics compare to Xeris Biopharma?

Summary

How does Akebia Therapeutics compare to Maravai LifeSciences?

Summary

How does Akebia Therapeutics compare to CureVac?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akebia Therapeutics (AKBA) Competitors

AKBA vs. AVLN, COLL, XERS, MRVI, and CVAC

How does Akebia Therapeutics compare to Avalyn Pharma?

Which has preferable valuation & earnings, AKBA or AVLN?

Is AKBA or AVLN more profitable?

Do institutionals and insiders hold more shares of AKBA or AVLN?

Does the media favor AKBA or AVLN?

Do analysts recommend AKBA or AVLN?

Summary

How does Akebia Therapeutics compare to Collegium Pharmaceutical?

Does the media prefer COLL or AKBA?

Do institutionals & insiders hold more shares of COLL or AKBA?

Which has more volatility & risk, COLL or AKBA?

Which has higher earnings and valuation, COLL or AKBA?

Do analysts recommend COLL or AKBA?

Is COLL or AKBA more profitable?

Summary

How does Akebia Therapeutics compare to Xeris Biopharma?

Do analysts recommend XERS or AKBA?

Which has stronger valuation and earnings, XERS or AKBA?

Which has more risk and volatility, XERS or AKBA?

Is XERS or AKBA more profitable?

Does the media prefer XERS or AKBA?

Do insiders & institutionals hold more shares of XERS or AKBA?

Summary

How does Akebia Therapeutics compare to Maravai LifeSciences?

Which has more volatility and risk, MRVI or AKBA?

Do analysts rate MRVI or AKBA?

Is MRVI or AKBA more profitable?

Do institutionals & insiders have more ownership in MRVI or AKBA?

Does the media prefer MRVI or AKBA?

Which has better valuation and earnings, MRVI or AKBA?

Summary

How does Akebia Therapeutics compare to CureVac?

Do analysts rate CVAC or AKBA?

Which has more risk and volatility, CVAC or AKBA?

Which has better earnings and valuation, CVAC or AKBA?

Is CVAC or AKBA more profitable?

Does the media refer more to CVAC or AKBA?

Do insiders and institutionals hold more shares of CVAC or AKBA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools